Innaxon

Melatonin Lipodisq™ Sterile Solution

As low as CHF 244.00

In stock

Only %1 left

IAX-700-102-L0011 mlCHF 244.00

More Information
Product Details
Synonyms	N-Acetyl-5-methoxytryptamine; NSC 56423; NSC 113928; Regulin
Product Type	Chemical
Properties
Formula	C₁₃H₁₆N₂O₂
MW	232.28
CAS	73-31-4
RTECS	AC5955000
Purity Chemicals	≥95% (HPLC)
Appearance	Colourless clear aqueous solution
Solubility	Soluble in water, PBS, Tris and other physiological solutions as formulated in a proprietary, thermostable, aqueous lipid nanoparticulate formulation (Lipodisq).
Reconstitution	Avoid the use of buffers with divalent ions such as Ca or Mg or pH <6.5 or >8.0, which can cause particle instability. Unformulated melatonin is soluble in DMF, DMSO or ethanol.
Formulation	Liquid, detergent-free discoidal nano-formulation made of styrene-maleic acid lipid particles (SMALP), lecithin and sterile water.
Concentration	1mg/ml (0.1% w/vol)
Biological Activity	Discoidal nano-particles can incorporate hydrophobic, poorly water-soluble compounds, such as lipids, lipoproteins and glycolipids. - Cell culture tested (human macrophage cell line) (MTT). - Recommended starting dilution: 1:200 or higher. - Optimal working concentrations depend on the applications and need to be determined. - Published procedures using Lipodisq formulations (Curcumin and IAXO TLR4 antagonists) in vivo rodent models at 3-10mg/kg. Recommended route of administration is subcutaneous (s.c.) with oral or nasal application as a possible alternative, which needs to be optimized.
Declaration	Manufactured by Innaxon.
Other Product Data	Click here for Original Manufacturer Product Datasheet: Our product description may differ slightly from the original manufacturers product datasheet. Lipodisq™ technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending. The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only, but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.
InChi Key	DRLFMBDRBRZALE-UHFFFAOYSA-N
Smiles	CC(NCCC1=CNC2=CC=C(OC)C=C21)=O
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	+4°C
Handling Advice	Keep sterile. Avoid skin and eye contact.
Use/Stability	Stable for at least 1 year after receipt when stored at +4°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Product References

Mechanisms of Melatonin in Alleviating Alzheimer’s Disease: M. Shukla, et al.; Curr. Neuropharmacol. 15, 1010 (2017)
Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases: D Chen, et al.; Biomolecules 10, 1158 (2020)
Melatonin and Pathological Cell Interactions: Mitochondrial Glucose Processing in Cancer Cells: R.F. Reiter, et al.; Int. J. Mol. Sci. 22, 12494 (2021)
Melatonin and Phytomelatonin: Chemistry, Biosynthesis, Metabolism, Distribution and Bioactivity in Plants and Animals—An Overview: G. Mannino, et al.; Int. J. Mol. Sci. 22, 9996 (2021)
Bacteriostatic Potential of Melatonin: Therapeutic Standing and Mechanistic Insights: F. He, et al.; Front. Immunol. 12, 683879 (2021)
Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder: S. Sebastien Lalanne, et al.; Int. J. Mol. Sci. 22, 1490 (2021)
Mechanisms of Melatonin in Obesity: A Review: Q. Guan; Int. J. Mol. Sci. 23, 218 (2022)
Protective Role of Melatonin and Its Metabolites in Skin Aging: G. Georgeta Bocheva, et al.; Int. J. Mol. Sci. 23, 1238 (2022)
Membrane Melatonin Receptors Activated Cell Signaling in Physiology and Disease: G. Nikolaev, et al.; Int. J. Mol. Sci. 23, 471 (2022)
New insights into the role of melatonin in diabetic cardiomyopathy: K. Huang, et al.; Pharmacol. Res. Perspect. 10, e00904 (2022)
Use of Melatonin in Cancer Treatment: Where Are We? L. Wang, et al.; Int. J. Mol. Sci. 23, 3779 (2022)

General References for Lipodisq™ Technology:

Responsive Hydrophobically Associating Polymers: A Review of Structure and Properties: S.R. Tonge & B.J. Tighe; Adv. Drug Deliv. Rev. 53, 109 (2001)
Detergent-free formation and physico-chemical characterization of nanosized lipidpolymer complexes: Lipodisq; M.C. Orwick, et al.; Angew. Chem. 51, 4653 (2012)
Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin: M.L. Torgersen, et al.; J. Biomed. Nanotechnol. 16, 41 (2020)
Applications of Synthetic Polymer Discoidal Lipid Nanoparticles to Biomedical Research: M. Tanaka; Chem. Pharm. Bull. 70, 507 (2022)
Mechanisms of Formation, Structure, and Dynamics of Lipoprotein Discs Stabilized by Amphiphilic Copolymers: A Comprehensive Review: P.S. Orekhov, et al.; Nanomaterials 12, 361 (2022)

Call	+41 61 926 6040
Fax	+41 61 926 6049